BioCryst Pharmaceuticals (BCRX) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liquidia (LQDA) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 16.4% versus a gain of 13.9%. Over five years, LQDA leads with a +775.6% price change compared with -45.2% for BCRX. Liquidia is the larger company by market cap ($2.43 billion vs $2.14 billion), about 1.1 times the size.
On valuation, BioCryst Pharmaceuticals trades at a lower forward P/E (8.9x vs 11.3x for Liquidia). BioCryst Pharmaceuticals converts more of its revenue into profit, with a net margin of 30.2% versus -43.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | LQDA |
|---|---|---|
| Share price | $8.39 | $27.15 |
| Market cap | $2.14B | $2.43B |
| 1-day change | +1.21% | -3.10% |
| YTD return | +6.28% | -18.76% |
| 1-year return | +13.87% | +16.36% |
| 5-year return | -45.21% | +775.63% |
| P/E ratio (TTM) | — | 19.53 |
| Forward P/E | 8.93 | 11.29 |
| EPS (TTM) | $-1.40 | $1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | $158.32M |
| Revenue growth (YoY) | +94.10% | +1031.18% |
| Net income (latest FY) | $263.86M | $-68.92M |
| Gross margin | 97.82% | — |
| Operating margin | 38.98% | -32.45% |
| Net margin | 30.16% | -43.53% |
| 52-week high | $11.22 | $93.61 |
| 52-week low | $6.00 | $21.94 |
| Distance from 52-week high | -25.22% | -71.00% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +147.08% | +82.95% |
| Average volume | 4.13M | 2.47M |
| Shares outstanding | 255.54M | 89.51M |
| Employees | 435 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioCryst Pharmaceuticals is more profitable, keeping 30.2 cents of every revenue dollar as net income versus -43.5 cents for Liquidia.
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs +94.10%).
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
BCRX vs LQDA FAQ
Which is bigger, BioCryst Pharmaceuticals or Liquidia?
Liquidia (LQDA) is larger, with a market capitalization of $2.43B compared with $2.14B for BioCryst Pharmaceuticals (BCRX).
Which stock has performed better over the past year, BCRX or LQDA?
LQDA returned +16.36% over the past 12 months, compared with +13.87% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Liquidia in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioCryst Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Liquidia.